Decoding Healthcare ETFs: Different Sectors, Different Strategies
Key PointsWhile State Street SPDR S&P Biotech ETF delivered a higher 1-year total return, the Invesco fund has experienced significantly shallower drawdowns and stronger cumulative growth over the past five years.
The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) and the State Street SPDR S&P Biotech ETF (XBI) are two distinct healthcare ETFs with varying strategies and risk-reward profiles. RSPH offers balanced exposure to the healthcare sector, tracking an equal-weighted index with 98% of its assets in healthcare and small exposures to technology.
It has a higher dividend yield of 0.6% and a stronger 5-year CAGR of 6.6%, making it an appealing option for investors seeking long-term, stable growth. On the other hand, XBI is more focused and volatile, targeting the biotechnology sector with 99% of its portfolio dedicated to healthcare and biotech stocks. While it has a lower dividend yield of 0.4%, its 5-year CAGR of 2.6% may still appeal to investors seeking higher growth potential.
Ultimately, the choice between these two ETFs will depend on an investor's risk tolerance, investment horizon, and specific goals.
Brief written by urgent.news from Motley Fool's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
